|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
EBSCO_ocn985198041 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
170501s2017 nyu ob 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d N$T
|d EBLCP
|d N$T
|d OCLCF
|d OCLCQ
|d AGLDB
|d IGB
|d AUW
|d BTN
|d MHW
|d INTCL
|d SNK
|d G3B
|d S8I
|d S8J
|d STF
|d D6H
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 985105705
|a 985390588
|a 985689404
|a 985954774
|a 986200795
|a 986273762
|a 986669297
|a 986852612
|
| 020 |
|
|
|a 9781536110180
|q (electronic bk.)
|
| 020 |
|
|
|a 1536110183
|q (electronic bk.)
|
| 020 |
|
|
|z 1536110116
|
| 020 |
|
|
|z 9781536110111
|
| 035 |
|
|
|a (OCoLC)985198041
|z (OCoLC)985105705
|z (OCoLC)985390588
|z (OCoLC)985689404
|z (OCoLC)985954774
|z (OCoLC)986200795
|z (OCoLC)986273762
|z (OCoLC)986669297
|z (OCoLC)986852612
|
| 050 |
|
4 |
|a RC267
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/4
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Horizons in cancer research.
|n Volume 66 /
|c Hiroto S. Watanabe, editor.
|
| 260 |
|
|
|a New York :
|b Nova Science Publishers, Inc.,
|c 2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Preface; Chapter 1; Chronic Myeloid Leukemia: Diagnosis, Treatment Options and Clinical Approaches; Abstract; Introduction; Clinical and Laboratory Features; Disease Evolution; Molecular Pathogenesis; Diagnosis; Treatment Options; Disease Monitoring; Hematologic Responses; Cytogenetic Responses; Molecular Responses; Definition of Clinical Response and Withholding of TKI Therapy; TKI Resistance and Mutational Analysis; References; Biographical Sketches; Chapter 2; Self-Esteem and Social Relationships in Preadolescents and Adolescents Who Survived Pediatric Leukemia; Abstract.
|
| 505 |
8 |
|
|a 1. Introduction1.1. Theoretical Framework; 1.2. Self-Esteem and Social Relationships in Childhood Cancer Survivors; 1.3. Study Aims and Hypothesis; 2. Method; 2.1. Participants; 2.2. Procedure; 2.3. Instruments; 2.3.1. Multidimensional Self-Esteem Test (TMA, Bracken, 1992; Italian version Mazzeo, 2003); 2.3.2. Ecocultural-Family Interview-Cancer, Pediatric Cancer Survivors' Version; 2.3.3. SES Questionnaire; 3. Results; 3.1. Self-Esteem Scoring, Present Well-being and Social Relationships in Preadolescents and Adolescents.
|
| 505 |
8 |
|
|a 3.2. Associations between Self-Esteem Scoring and Illness Variables3.3. Associations between dimensions of EFI-C Pediatric Cancer Survivors' Version with Self-Esteem Scoring; 4. Discussion; References; Chapter 3; The Role of Lactoferrin Expression in Initiation and Progression of Most Common Hormone-Dependent Cancers; Abstract; Abbreviations; Introduction; Study of LF Expression in Benign and Malignant Breast and Prostate Tumors; Relationship between LF Expression in Benign and Malignant Breast Tumors Based on Clinical and Pathological Features of the Tumor Progression.
|
| 505 |
8 |
|
|a LF Expression in Malignant and Benign Prostate Tumor TissuesConclusion; References; Chapter 4; ETS Transcription Factor FLI-1 as an Important Player in Human Cancer; Abstract; Introduction; Friend Leukemia Integration-1 (Fli-1); Fli-1 Target Genes; The Role of Fli-1 in Malignant Transformation; Fli-1 Inhibitors; Increased Level of Fli-1 Messenger RNA in Bone Marrow and Blood Mononuclear Cells of MDS Patients with 5q- Syndrome; Increased FLI-1 Transcriptional Activity can Inhibit Tumor Growth in Erythroleukemia and Probably Some Other Cancers; Conclusion and Perspectives; Acknowledgments.
|
| 505 |
8 |
|
|a Conflict of InterestReferences; Chapter 5; From DNA Methylation Signature in Circulating DNA to Cancer Detection and Monitoring; Abstract; 1. Introduction; 2. Circulating Tumor Cells and Cell-Free Tumor DNA; 3. The Utility of DNA Methylation Signature as a Tumor Biomarker; 3.1. Tumor-Specific Gene Methylations; 4. Analytical Methods; 5. DNA Methylation Biomarkers in ctDNA for Clinical Use; 5.1. Cancer Screening and Early Detection; 5.2. Prediction of Response to Chemotherapy; 5.2.1. Therapies with Demethylating Drugs; 5.3. Determination of Prognosis; 6. Future Perspective; References.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
0 |
|a Cancer
|x Treatment.
|
| 650 |
|
6 |
|a Cancer
|x Recherche.
|
| 650 |
|
6 |
|a Cancer
|x Traitement.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|x Research
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Treatment
|2 fast
|
| 700 |
1 |
|
|a Watanabe, Hiroto S.
|
| 776 |
0 |
8 |
|i Print version:
|t Horizons in cancer research. Volume 66.
|d New York : Nova Science Publishers, Inc., 2017
|z 1536110116
|z 9781536110111
|w (OCoLC)973751162
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1512210
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4849163
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1512210
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 14267261
|
| 994 |
|
|
|a 92
|b IZTAP
|
